- Home
- ICCC vs CUE Comparison
ICCC vs CUE Comparison
Compare ICCC & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICCC
- CUE
- Stock Information
- Founded
- ICCC 1982
- CUE 2014
- Country
- ICCC United States
- CUE United States
- Employees
- ICCC N/A
- CUE N/A
- Industry
- ICCC Biotechnology: Pharmaceutical Preparations
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- ICCC Health Care
- CUE Health Care
- Exchange
- ICCC Nasdaq
- CUE Nasdaq
- Market Cap
- ICCC 60.1M
- CUE 59.5M
- IPO Year
- ICCC 1987
- CUE 2018
- Fundamental
- Price
- ICCC $5.92
- CUE $0.74
- Analyst Decision
- ICCC
- CUE Strong Buy
- Analyst Count
- ICCC 0
- CUE 2
- Target Price
- ICCC N/A
- CUE $3.00
- AVG Volume (30 Days)
- ICCC 7.7K
- CUE 116.9K
- Earning Date
- ICCC 11-12-2025
- CUE 08-12-2025
- Dividend Yield
- ICCC N/A
- CUE N/A
- EPS Growth
- ICCC N/A
- CUE N/A
- EPS
- ICCC 0.20
- CUE N/A
- Revenue
- ICCC $28,274,756.00
- CUE $8,286,000.00
- Revenue This Year
- ICCC N/A
- CUE N/A
- Revenue Next Year
- ICCC N/A
- CUE $10.19
- P/E Ratio
- ICCC $30.55
- CUE N/A
- Revenue Growth
- ICCC 21.75
- CUE N/A
- 52 Week Low
- ICCC $3.34
- CUE $0.45
- 52 Week High
- ICCC $7.60
- CUE $1.99
- Technical
- Relative Strength Index (RSI)
- ICCC 41.72
- CUE 38.09
- Support Level
- ICCC $6.29
- CUE $0.77
- Resistance Level
- ICCC $6.42
- CUE $0.79
- Average True Range (ATR)
- ICCC 0.24
- CUE 0.04
- MACD
- ICCC -0.02
- CUE -0.01
- Stochastic Oscillator
- ICCC 1.82
- CUE 12.87
About ICCC ImmuCell Corporation
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.